Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

Early intensification by (un)related allogeneic or autologous stem cell transplantation in adult acute lymphoblastic leukemia. A phase II study.

- candidate number1401
- NTR NumberNTR228
- Date ISRCTN created20-dec-2005
- date ISRCTN requested18-okt-2005
- Date Registered NTR6-sep-2005
- Secondary IDsHO37 
- Public TitleEarly intensification by (un)related allogeneic or autologous stem cell transplantation in adult acute lymphoblastic leukemia. A phase II study.
- Scientific TitleEarly intensification by (un)related allogeneic or autologous stem cell transplantation in adult acute lymphoblastic leukemia. A phase II study.
- hypothesisPatients who are in 1st CR after autologous transplantation, may be randomized between no further treatment (arm A) and maintenance chemotherapy (arm B). The hypothesis to be tested is that maintenance therapy will prolong disease free survival, calculated from the date of randomization.
- Healt Condition(s) or Problem(s) studiedAcute Lymphoblastic Leukemia
- Inclusion criteria1. Age between 16 and 59 (inclusive) years;
2. Previously untreated with chemotherapy;
3. ALL according to the FAB criteria and immunological marker analysis (B-precursor ALL, T-ALL and AUL);
4. WHO performance status grade 0, 1, 2 or 3;
5. Patient informed consent.
- Exclusion criteria1. B-ALL (= mature B-ALL);
2. Severe cardiac, pulmonary, hepatic, renal, neurologic, psychiatric or metabolic disease;
3. Second malignant disease, except cervix carcinoma stage I and non-melanoma skin cancer;
4. Persisting renal insufficiency, creatinine more than 200 mmol/l;
5. Active uncontrolled infections;
6. HIV positivity on serological tests.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingNone
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-apr-1999
- planned closingdate1-nov-2005
- Target number of participants200
- InterventionsAll patients will receive early intensification:
- cycle 1: prednisone, vincristine, daunorubicin, aspariganse, MTX i.t.
- cycle 2: Cytarabine, Mitoxantrone, MTX i.t.
- cycle 3: Methotrexate, asparaginase, 6-MP, MTX i.t.
After intensification patients will receive either an allogeneic sibling stem cell transplantation, a matched unrelated donor stem cell transplantation or an autologous stem cell transplantation.
Patients who received an autologous stem cell transplantation will be randomized between:
- Arm A: no further treatment.
- Arm B: maintenance treatment with 6-MP and MTX.
- Primary outcomeResponse after each course of chemotherapy and date of CR.
- Secondary outcome1. Disease-free survival (i.e. time from achievement of first CR to the date of relapse or death from any cause, whichever occurs first);
2. Event-free survival (i.e., time from start of therapy to the date of no complete response, death or relapse whichever occurs first): this takes into consideration induction failures and toxic deaths. The time to failure of patients with induction failure is set at one day;
3. Overall survival will be measured from time of registration until death or last contact;
4. Toxicities and treatment related mortality.
- TimepointsN/A
- Trial web site
- statusinclusion stopped: follow-up
- Sponsor/Initiator VU University Medical Center, Dutch haemato-oncology association (Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Erasmus Medical Center, Daniel den Hoed Cancer Center
- Funding
(Source(s) of Monetary or Material Support)
Koningin Wilhelmina Fonds (KWF), Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON)
- PublicationsN/A
- Brief summaryStudy phase:
phase 2.

Study objectives:
1. To study prospectively the value of early intensification by allogeneic or autologous stem cell transplantation in ALL;
2. To study prospectively stem cell transplantation with a matched unrelated donor in high-risk ALL when no sibling donor is available;
3. To study the value of donor lymphocyte infusion (DLI) in high-risk ALL with a molecular or cytogenetic relapse after allogeneic stem cell transplantation or in high-risk ALL with persistent residual disease (molecular; cytogenetic);
4. To study the value of maintenance chemotherapy in ALL patients after autologous transplantation;
5. To study leukemic cell reduction by means of (semi-quantitative) molecular techniques during induction chemotherapy, after consolidation with stem cell transplantation, and during maintenance chemotherapy in patients receiving an autologous stem cell transplantation.

Patient population:
Patients with previously untreated, B-precursor ALL, T-ALL or AUL, age 16-59 years inclusive.

Study design:
Prospective, multicenter, randomized.
- Main changes (audit trail)
- RECORD6-sep-2005 - 15-sep-2008

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar